Lilly Endowment Inc's Form 4 filing
Eli Lilly & Co (LLY) · filed Feb 26, 2025
- Accession no.
- 0001415889-25-005670
- Filed
- Feb 26, 2025
- Trade date
- Feb 25, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 12 non-derivative transactions. Open-market sales total $203.2M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lilly Endowment IncCIK 0000316011 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2025 | Common Stock | SSaleDisposed | −35,578 | $900.50F1 | −$32,037,989 | 96,426,400 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −50,118 | $901.57F2 | −$45,184,885.26 | 96,376,282 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −47,905 | $902.49F3 | −$43,233,783.45 | 96,328,377 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −36,219 | $903.48F4 | −$32,723,142.12 | 96,292,158 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −18,159 | $904.54F5 | −$16,425,541.86 | 96,273,999 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −11,143 | $905.41F6 | −$10,088,983.63 | 96,262,856 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −8,559 | $906.46F7 | −$7,758,391.14 | 96,254,297 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −4,962 | $907.29F8 | −$4,501,972.98 | 96,249,335 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −5,191 | $908.29F9 | −$4,714,933.39 | 96,244,144 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −3,290 | $909.38F10 | −$2,991,860.2 | 96,240,854 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −3,606 | $910.53F11 | −$3,283,371.18 | 96,237,248 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −270 | $911.55F12 | −$246,118.5 | 96,236,978 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $900.00 to $900.99, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), and (12) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $901.00 to $901.995, inclusive.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $902.00 to $902.995, inclusive.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $903.00 to $903.995, inclusive.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $904.00 to $904.995, inclusive.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $905.00 to $905.995, inclusive.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $906.00 to $906.955, inclusive.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $907.00 to $907.995, inclusive.
Referenced by the price of 1 transaction in Table I.
- F9
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $908.00 to $908.935, inclusive.
Referenced by the price of 1 transaction in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $909.045 to $910.00, inclusive.
Referenced by the price of 1 transaction in Table I.
- F11
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $910.11 to $911.04, inclusive.
Referenced by the price of 1 transaction in Table I.
- F12
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $911.45 to $911.66, inclusive.
Referenced by the price of 1 transaction in Table I.